Search

Your search keyword '"Michael D. Miller"' showing total 432 results

Search Constraints

Start Over You searched for: Author "Michael D. Miller" Remove constraint Author: "Michael D. Miller"
432 results on '"Michael D. Miller"'

Search Results

101. PD-1 Blockade in Rhesus Macaques: Impact on Chronic Infection and Prophylactic Vaccination

102. Comparison of Opioid Requirements and Analgesic Response in Opioid-Tolerant versus Opioid-Naïve Patients After Total Knee Arthroplasty

103. Social impact in technologically-mediated communication: An examination of online influence

104. Short-Lived Infected Cells Support Virus Replication in Sooty Mangabeys Naturally Infected with Simian Immunodeficiency Virus: Implications for AIDS Pathogenesis

105. Simian Immunodeficiency Virus SIVagm Dynamics in African Green Monkeys

106. Monitoring the development of non-nucleoside reverse transcriptase inhibitor-associated resistant HIV-1 using an electrochemiluminescence-based reverse transcriptase polymerase assay

107. Prevalence, Genotypic Associations and Phenotypic Characterization of K65R, L74V and other HIV-1 RT Resistance Mutations in a Commercial Database

108. A Progress Report On State Health Access Reform

109. Rapid and Durable Antiretroviral Effect of the HIV-1 Integrase Inhibitor Raltegravir as Part of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection

110. In Vitro Drug Susceptibility Analysis of Hepatitis B Virus Clinical Quasispecies Populations

111. Low-Level K65R Mutation in HIV-1 Reverse Transcriptase of Treatment-Experienced Patients Exposed to Abacavir or Didanosine

112. Effects of the Translocation Status of Human Immunodeficiency Virus Type 1 Reverse Transcriptase on the Efficiency of Excision of Tenofovir

113. Automated high-throughput purification of antibody fragments to facilitate evaluation in functional and kinetic based assays

114. Emergent HIV-1 Drug Resistance Mutations Were Not Present at Low-Frequency at Baseline in Non-Nucleoside Reverse Transcriptase Inhibitor-Treated Subjects in the STaR Study

115. Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations

116. Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir

117. Drug Susceptibility and Viral Fitness of HIV-1 with Integrase Strand Transfer Inhibitor Resistance Substitution Q148R or N155H in Combination with Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Resistance Substitutions

118. A Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals

119. Genotype- and Subtype-Independent Full-Genome Sequencing Assay for Hepatitis C Virus

120. Characterization of HIV-1 Resistance to Tenofovir Alafenamide In Vitro

122. A Cell-Based Strategy To Assess Intrinsic Inhibition Efficiencies of HIV-1 Reverse Transcriptase Inhibitors

123. Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin

124. In Vitro Human Immunodeficiency Virus Type 1 Resistance Selections with Combinations of Tenofovir and Emtricitabine or Abacavir and Lamivudine

125. In Vitro Susceptibility of Adefovir-Associated Hepatitis B Virus Polymerase Mutations to other Antiviral Agents

126. The K65R Reverse Transcriptase Mutation in HIV-1 Reverses the Excision Phenotype of Zidovudine Resistance Mutations

127. A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT

128. A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope

129. Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection

130. Cross-Resistance Testing of Next-Generation Nucleoside and Nucleotide Analogues against Lamivudine-Resistant HBV

131. Gallery of Medical Devices

132. Lack of a Metabolic and Antiviral Drug Interaction between Tenofovir, Abacavir and Lamivudine

133. Predictors of Residual Viremia in HIV‐Infected Patients Successfully Treated with Efavirenz and Lamivudine plus either Tenofovir or Stavudine

134. In VitroEvaluation of the Anti-HIV Activity and Metabolic Interactions of Tenofovir and Emtricitabine

135. Diminished Replicative Fitness of Primary Human Immunodeficiency Virus Type 1 Isolates Harboring the K65R Mutation

136. In VitroCombination Studies of Tenofovir and Other Nucleoside Analogues with Ribavirin against HIV-1

137. Dissecting the Effects of DNA Polymerase and Ribonuclease H Inhibitor Combinations on HIV-1 Reverse-Transcriptase Activities

138. Synthesis and biological evaluation of 5R- and 5S-methyl substituted d- and l-configuration 1,3-dioxolane nucleoside analogs

139. Syntheses and SAR studies of 4-(heteroarylpiperdin-1-yl-methyl)-pyrrolidin-1-yl-acetic acid antagonists of the human CCR5 chemokine receptor

140. HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications

141. Coupling of Human Immunodeficiency Virus Type 1 Fusion to Virion Maturation: a Novel Role of the gp41 Cytoplasmic Tail

142. Highly Uneven Distribution of Tenofovir-Selected Simian Immunodeficiency Virus in Different Anatomical Sites of Rhesus Macaques

143. Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 3: SAR studies on the benzylpyrazole segment

144. Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 1: Discovery and SAR study of 4-pyrazolylpiperidine side chains

145. Mechanistic Basis for Reduced Viral and Enzymatic Fitness of HIV-1 Reverse Transcriptase Containing Both K65R and M184V Mutations

146. Resistance Analysis in 1284 Patients with Genotype 1 to 6 HCV Infection Treated with Sofosbuvir/Velpatasvir in the Phase 3 Astral-1, Astral-2, Astral-3 and Astral-4 Studies

147. Resistance Analyses for Ledipasvir/Sofosbuvir Containing Regimens in Patients Infected with Chronic HCV who Have Advanced Liver Disease or are Post Liver Transplant (Solar-1 & 2 Studies)

148. Resistance Analysis of Genotype 1 or 3 HCV-Infected Patients Treated with Sofosbuvir/Velpatasvir+GS-9857 for 6 or 8 Weeks

149. The Hepatitis B Virus Polymerase Mutation rtV173L Is Selected during Lamivudine Therapy and Enhances Viral Replication In Vitro

150. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1 1Gilead Sciences gratefully acknowledges the patients, investigators, and study site personnel who participated in clinical trials GS-98-437 and GS-98-438

Catalog

Books, media, physical & digital resources